Advertisement
Singapore markets closed
  • Straits Times Index

    3,272.72
    +47.55 (+1.47%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • Dow

    38,239.98
    +253.58 (+0.67%)
     
  • Nasdaq

    15,451.31
    +169.30 (+1.11%)
     
  • Bitcoin USD

    66,138.59
    +92.16 (+0.14%)
     
  • CMC Crypto 200

    1,420.80
    +6.04 (+0.43%)
     
  • FTSE 100

    8,069.03
    +45.16 (+0.56%)
     
  • Gold

    2,314.00
    -32.40 (-1.38%)
     
  • Crude Oil

    81.51
    -0.39 (-0.48%)
     
  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     
  • Nikkei

    37,552.16
    +113.55 (+0.30%)
     
  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     
  • FTSE Bursa Malaysia

    1,561.64
    +2.05 (+0.13%)
     
  • Jakarta Composite Index

    7,110.81
    +36.99 (+0.52%)
     
  • PSE Index

    6,506.80
    +62.72 (+0.97%)
     

Analyst Ratings for UniQure and Its Peers in April 2018

Analyst Ratings for UniQure and Its Peers in April 2018

UniQure (QURE) is a leading company in the field of gene therapy. It has a focused pipeline of innovative gene therapies developed both internally and through collaboration for cardiovascular diseases. It has established clinical proof of concept for its lead indication, hemophilia B, and has achieved preclinical proof of concept in Huntington’s disease.